Do PBMs, drug market brokers, have a stranglehold on prices that even Congress can’t break?

The FTC under President Joe Biden has switched course, at least partly because of the arrival of Chair Lina Khan, a vigorous proponent of antitrust policy who launched an investigation of the PBMs last June.

And her reimbursements are “beyond low,” Seyfarth said. She laughed when asked whether contract terms with the PBMs were negotiable. “You aren’t negotiating anything,” she said. “It’s take it or leave it.” In October 2021, St. Clair’s treatment for a rare, non-smoking-related lung cancer was delayed three weeks after PBM giant Express Scripts insisted her prescription be filled by Accredo, the mail-order pharmacy it owns.

ประเทศไทย ข่าวล่าสุด, ประเทศไทย หัวข้อข่าว

Similar News:คุณยังสามารถอ่านข่าวที่คล้ายกันนี้ซึ่งเรารวบรวมจากแหล่งข่าวอื่น ๆ ได้

Do PBMs, drug market brokers, have a stranglehold on prices that even Congress can’t break?Drugmakers, pharmacies and physicians blame pharmacy benefit managers for high drug prices. Congress is finally on board, too, but will it matter?
แหล่ง: USATODAY - 🏆 100. / 63 อ่านเพิ่มเติม »